Share this on: Delicious Digg Facebook LinkedIn Twitter What is this? Previous Release | Next Release April 9, 2008 Enzon to Present Preclinical Data On HIF-1alpha antagonist at AACR Company will host informative reception BRIDGEWATER, N.J., Apr 09, 2008 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc...

HOME ABOUT ENZON Overview Executive Team Board of Directors Scientific Advisory Board CLINICAL DEVELOPMENT Overview Presentations & Publications TECHNOLOGY PLATFORMS ROYALTY PRODUCTS INVESTORS & MEDIA Overview Press Releases Events and Presentations Analyst Coverage Annual Reports Corporate ...

Share this on: Delicious Digg Facebook LinkedIn Twitter What is this? Previous Release | Next Release October 30, 2007 Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist Study to evaluate additional dosing schedule BRIDGEWATER, N.J., Oct 30, 2007 (BUSINESS WIRE) -- Enzon Pharmaceutic...

Share this on: Delicious Digg Facebook LinkedIn Twitter What is this? Previous Release | Next Release March 17, 2008 Enzon's PEG-SN38 Featured in Clinical Cancer Research Data demonstrates PEG-SN38 markedly inhibits tumor growth BRIDGEWATER, N.J., Mar 17, 2008 (BUSINESS WIRE) -- Enzon Pharmaceutical...